Jodie L. Simpson, Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Christine Jenkins, Matthew J. Peters, Guiquan Jia, Cecile T. J. Holweg and Peter G. Gibson

Periostin levels and eosinophilic inflammation in poorly-controlled asthma
BMC Pulmonary Medicine, 2016; 16(1):67-1-67-7

© Simpson et al. 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Originally published at:
http://doi.org/10.1186/s12890-016-0230-4

http://creativecommons.org/licenses/by/4.0/

http://hdl.handle.net/2440/100620
Periostin levels and eosinophilic inflammation in poorly-controlled asthma

Jodie L. Simpson1,2*, Ian A. Yang3,4, John W. Upham3,5, Paul N. Reynolds6,7, Sandra Hodge6,7, Alan L. James8,9, Christine Jenkins10,12, Matthew J. Peters11,12, Guilquan Jia13, Cecile T. J. Holweg13 and Peter G. Gibson1,2,14

Abstract

Background: Periostin levels are associated with airway eosinophilia and are suppressed by corticosteroid treatment in asthma. This study sought to determine the relationship between serum and sputum periostin, airway inflammatory phenotype and asthma control.

Methods: Adults with poorly-controlled asthma (n = 83) underwent a clinical assessment, sputum induction and blood sampling. Dispersed sputum was used for a differential cell count and periostin assessment (ELISA). Serum periostin was determined by the Elecsys® immunoassay.

Results: Periostin levels were significantly higher in serum (median (IQR) of 51.6 (41.8, 62.6) ng/mL) than in sputum (1.1 (0.5, 2.0) ng/mL) (p < 0.001). Serum and sputum periostin were significantly higher in patients with eosinophilic asthma (n = 37) compared with non-eosinophilic asthma. Both serum and sputum periostin levels were significantly associated with proportion of sputum eosinophils (r = 0.422, p < 0.001 and r = 0.364, p = 0.005 respectively) but were not associated with asthma control. In receiver operator characteristic curve analysis, the area under the curve (AUC) for serum periostin (n = 83) was 0.679, p = 0.007. Peripheral blood eosinophils assessed in 67 matched samples, had a numerically greater AUC of 0.820 compared with serum periostin, p = 0.086 for the detection of eosinophilic asthma.

Conclusion: In poorly-controlled asthma, sputum and serum periostin levels are significantly related to sputum eosinophil proportions while their ability to predict the presence of eosinophilic asthma is modest.

Keywords: Periostin, Eosinophilic asthma, Non-eosinophilic asthma, Phenotype, Inflammation

Background

Asthma is a chronic heterogeneous inflammatory disorder of the airways where approximately 50% of adults have eosinophilic airway inflammation which is referred to as eosinophilic asthma. Sputum eosinophils are an effective monitoring tool in asthma when used in therapeutic decision making and there is good evidence that this approach can significantly reduce severe exacerbations [1, 2]. The technical difficulties associated with sputum collection and processing limit the use of this management strategy in clinical practice. Alternative and accurate biomarkers that can predict sputum eosinophils are needed to facilitate inflammation-based asthma management.

We have recently shown that blood eosinophil counts are a suitable surrogate for sputum eosinophil proportion in identifying patients with eosinophilic asthma, being simple and readily available and thus may provide a suitable asthma management tool [3]. Similarly, reports also show that serum periostin levels are associated with airway eosinophilia in asthma [4]. In bronchial brushings, periostin gene expression is upregulated in a subset of patients in which it was associated with the expression of Th2 cytokines. These patients also had higher blood and BAL eosinophil counts and were most responsive to inhaled corticosteroids (ICS) [5]. Periostin is expressed by lung epithelial cells and fibroblasts and in vitro experiments show that periostin is secreted by high eosinophilic inflammation.

*Correspondence: jodie.simpson@newcastle.edu.au
1Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Level 2, West Wing, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia
2Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, NSW, Australia

Full list of author information is available at the end of the article.

© 2016 Simpson et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
towards the basolateral side of the airway [6, 7]. However, little is known about the airway levels of periostin and the relationships between airway periostin levels, asthma inflammatory subtypes and asthma control.

This study sought to examine the ability of serum periostin to predict the presence of eosinophilic asthma and to determine the relationship between airway and serum periostin levels, inflammatory subtype and asthma control in a group of adults with poorly-controlled asthma.

Methods
Study participants
Eligible adults with asthma (n = 83) who were participants in a randomised controlled trial of macrolides in asthma. The diagnosis of asthma was established using the American Thoracic Society guidelines based upon the presence of current episodic respiratory symptoms (past 12 months), doctor-confirmed diagnosis and evidence of variable airflow obstruction [8] (airway hyperresponsiveness, bronchodilator response or diurnal variation of peak expiratory flow). They also were prescribed maintenance ICS treatment and remained poorly-controlled with an Asthma Control Questionnaire 6 (ACQ6) score >0.7 [9]. Participants with an FEV₁ < 40 % predicted, current smokers, ex-smokers who had ceased smoking in the previous year and those with an exacerbation or respiratory infection in the past four weeks were excluded. Those with significant smoking-related emphysema (ex-smokers >10 pack year history and carbon monoxide transfer coefficient <70 % predicted) OR smoking history >10 pack years and exhaled carbon monoxide >10 ppm were also excluded.

Participants underwent a clinical assessment, allergy skin test, spirometry with bronchodilator response, sputum induction and blood sampling in turn. All tests were performed on the same day prior to the commencement of study medication. Measurements were carried out by observers blinded to other results.

Ethics, consent and permissions
Subjects gave written informed consent (Approval to the protocol was provided by the following ethics committees: Sir Charles Gairdner Group Human Research ethics committee (2008-147), Royal Adelaide Hospital Human Research Ethics Committee (081108f), Hunter New England Research Ethics Committee (08/11/19/3.03), The Prince Charles Hospital Metro North Hospital and Health Services (HREC/08/QPCH/4), Metro South Health Service District Human Research Ethics Committee (HREC/09/QPAH/015).

Study design
This cross-sectional study characterised participants during a single visit where symptoms, atopy, medication use and smoking status were assessed, and the spirometry and sputum induction and blood collection were undertaken. Sputum was processed for inflammatory cell counts and sputum supernatant and serum were stored for periostin analysis.

Sputum induction and analysis
Spirometry (CPF/DS™ USB Spirometer, BreezeSuite™ v7.1, MGC Diagnostics, Saint Paul, MN, USA) and induced sputum were performed. Sputum was induced by the inhalation of hypertonic saline (4.5 %) as described by Gibson et al. [10]. Subjects received a mean nebulization time of 13.7 min.

Sputum was processed as described [10]. Selected sputum portions were dispersed by dithiothreitol (DTT) (Merck Millipore, Darmstadt, Germany) and a total cell count performed. Cytospins were prepared and stained with May-Grünwald Giemsa. Cell counts were performed on 400 non-squamous cells. Cell viability and differential cell counts were recorded.

Asthma subtypes were defined by percentages of sputum eosinophils and neutrophils (of total inflammatory cells) and were classified as eosinophilic asthma if sputum eosinophils were ≥3 % and sputum neutrophils were <61 %, as previously defined [11].

Blood samples and periostin serum assessment
Venous blood samples were collected without anticoagulant. Periostin levels in serum were measured using the clinical trial version of the Elecsys® Periostin immunoassay (Roche Diagnostics, Penzberg, Germany) intended for use on the cobas e 601 immunology analyzer, an automated electrochemiluminescence immunoassay based on the sandwich principle [12]. Peripheral blood eosinophil counts were assessed in 67 participants which are part of a previously published dataset [3].

Periostin sputum assessment
Periostin levels in sputum were measured using the Genentech proprietary ELISA using the same antibody pair as the Elecsys® assay [4]. The limit of detection of the assay is 9.4 pg/mL.

Analysis
The results were expressed as mean ± SD for continuous variables and median with interquartile range (IQR) when data were not normally distributed. Categorical data were reported using frequencies and percentages. A Kruskal-Wallis test was performed in the different subgroups of subjects with asthma. Spearman’s rank correlation coefficient was used to assess the associations between non-parametric data. Results were reported as significant when p < 0.05. The performance characteristics of the periostin variables were examined by receiver
operating characteristic (ROC) curves to determine the concentrations which best defined eosinophilic asthma based on the sputum cell count. Participants were assigned to the high periostin group if their serum periostin levels were $\geq 50$ ng/mL [13].

**Results**

Participants consisted of 83 adults with a mean age of 61 years who were predominantly atopic (73 %) and poorly-controlled (mean ACQ6 1.83) on treatment (Table 1). A sputum cell count was available for 82/83 participants to assign inflammatory phenotype. Thirty-seven participants had eosinophilic asthma, defined as sputum eosinophils $\geq 3$ % and 45 had non-eosinophilic asthma. Most participants with non-eosinophilic asthma ($n = 28$) had a paucigranulocytic phenotype (34 %); 17 had neutrophilic phenotype (21 %) and five participants had a mixed eosinophilic and neutrophilic phenotype (6 %).

**Periostin levels in serum and sputum**

For all subjects, periostin levels were significantly higher in serum (51.6 (41.8, 62.6) ng/mL) than in sputum (1.11 (0.5, 2.0) ng/mL) ($p < 0.001$).

Sputum periostin was assessed at three dilutions, 1 in 2, 1 in 10 and 1 in 50. A matrix effect (a direct or indirect alternation or interference in the measurement of an analyte) was observed on assay linearity with increased concentrations of periostin measured when the sample was more diluted (four representative results are shown in Table 2). To control for this effect, sputum periostin levels were analysed at a single dilution. Using the 1:2 dilution, sputum periostin was detectable in 65/83 (78 %) samples, where most samples ($n = 59$) had sputum periostin concentrations within the assay dynamic quantitative range. Six samples had periostin levels that were beyond the maximum of quantitative range at 1:2 and 17 samples had levels that were below the detection level. Alternately, using the 1:10 dilution, sputum periostin was detectable in 35/83 (42 %) samples; this is significantly fewer when compared with the proportion of samples detected using the 1:2 dilution (78 % vs. 42 % $p = 0.045$). Subsequent analysis of sputum periostin was undertaken using the results from the 1:2 dilution.

We observed a reduction in periostin concentration assessed when periostin protein was diluted in a sputolysin containing diluent (see Additional file 1 and Additional file 2).

**Periostin levels and sputum eosinophils**

Sputum and serum periostin were significantly higher in patients with eosinophilic asthma compared with non-eosinophilic asthma (Fig. 1).

Both serum and sputum periostin levels were significantly associated with sputum eosinophils ($r = 0.422$, $p = 0.0001$ and $r = 0.364$, $p = 0.005$ respectively, Fig. 2).

In order to examine the utility of serum and sputum periostin to predict the presence of eosinophilic asthma ($\geq 3$ % sputum eosinophils) we generated ROC curves. The area under the curve (AUC) for sputum periostin was 0.754, $p < 0.001$, whereas for serum periostin the AUC was 0.680, $p = 0.005$ (Fig. 3). The AUC did not improve by using a 2 % sputum eosinophil cut-off point to distinguish eosinophilic from non-eosinophilic asthma (data not shown).

Peripheral blood eosinophil counts were available in only 67 participants. We compared the ability of blood eosinophils and serum periostin as a biomarker to predict the presence of eosinophilic asthma in the same 67 samples. Peripheral blood eosinophils had a more

---

**Table 1** Patient characteristics

| Number | 83 |
|--------|
| Age, mean (range) | 61 (21–82) |
| Sex, male (%) | 42 (51) |
| BMI, mean (SD) | 30.0 (5.5) |
| Atopy, n (%) | 61 (73) |
| Ex-smoker, n (%) | 34 (41) |
| Pack years, median (q1,q3) | 26 (2,40) |
| FEV$_1$ % predicted, mean (SD) | 72.2 (20.3) |
| FEV$_1$/FVC, mean (SD) | 0.66 (0.12) |
| GINA treatment step n (%) | |
| 3 | 14 (17) |
| 4 | 67 (81) |
| 5 | 2 (2) |
| ACQ6, mean (SD) | 1.83 (0.82) |
| ICS dose μg, median (q1,q3) | 1000 (800,2000) |
| Taking regular OCS, n (%) | 3 (4) |
| Sputum eosinophils %, median (q1,q3) | 2.1 (0.5,9.5) |
| Blood eosinophils, x10$^9$/mL, median (q1,q3), n = 67 | 0.23 (0.11, 0.40) |

BMI body mass index, ACQ6 Asthma Control Questionnaire 6, ICS inhaled corticosteroid dose (in CFC beclomethasone equivalents), OCS oral corticosteroids

**Table 2** Sputum periostin levels increased with increasing dilution of sputum supernatant

| ID     | Dilution |
|--------|----------|
| 24312  | 1:2      | 0.35 | 0.49 | 0.95 |
| 24327  | ND       | 0.17 | ND   |
| 24488  | 0.27     | 0.49 | 1.78 |
| 24586  | 0.47     | 0.36 | 1.21 |

Periostin results are shown as ng of periostin per mL of sputum supernatant
ND not detected
favourable AUC of 0.820 compared with an AUC of 0.704 for serum periostin, $p = 0.086$.

**Associations with clinical and inflammatory cell profile**
There was no association between mean asthma control score (ACQ6) and either sputum or serum periostin levels ($r = 0.038$ and $r = -0.062$, $p > 0.05$ respectively). Similarly, there was no difference in ACQ6 in those with high serum periostin ($\geq 50$ ng/mL) or low serum periostin (<50 ng/mL) levels (median ACQ6 1.8 vs 1.7, $p = 0.530$). Both sputum and serum periostin were significantly and inversely associated with body mass index (BMI) ($r = -0.368$, $p = 0.004$ and $r = -0.325$, $p = 0.003$ respectively) but not associated with ICS dose, smoking pack years, lung function or atopy. There was no difference in sputum or serum periostin levels in never smokers compared with ex-smokers (data not shown). Using logistic regression there was no improvement in the model to explain the presence of eosinophilic asthma by the addition of BMI to serum periostin levels.

**BMI and periostin**
Given the negative association observed between periostin levels and BMI we sought to determine if BMI impacted on the ability of serum periostin to predict the presence of eosinophilic asthma. The ability of serum periostin to predict the presence of eosinophilic asthma was not improved following correction for BMI, with a corrected AUC of 0.681, which was not statistically different to the uncorrected AUC of 0.680, $p = 0.551$.

**Discussion**
In this well-characterised cohort with poorly-controlled asthma, periostin was detected in 78 % of sputum samples at a 1:2 dilution. While levels of periostin in induced sputum were lower than those measured in serum, both sputum and serum periostin levels were significantly associated with airway eosinophilia. Additionally, both sputum and serum periostin levels were significantly higher in patients with eosinophilic asthma compared with non-eosinophilic asthma. Our data are supported by similar correlations between serum periostin and sputum eosinophils in other cohorts [4, 14].
It is unclear if the lower sputum periostin levels compared to serum are the result of limitations in detecting proteins in sputum supernatant samples processed with sputolysin, differences in the assays utilised in the detection of periostin or a biological difference between the sample types. The ELISA that was used for the assessment of sputum periostin was validated for the measurement of serum periostin, but not sputum and the matrix effect observed could influence the lower levels reported. Also, while both the serum and sputum assays use the same antibody pair, they use different platforms and reagents, which may lead to differences in sensitivity. Serum periostin was measured previously by Genentech using both assay platforms in 195 severe asthma serum samples and on average Elescsys® Periostin values were 2.03 times (+/- 0.01 s.e.) greater than those derived by ELISA (unpublished data). Since the assays have not been standardized against each other, the levels can not directly be compared. However, assay differences alone are unlikely to explain the 50-fold difference between sputum and serum periostin levels observed in this study and further investigation is required including an assessment of the variation of periostin levels over time in sputum.

There may also be a biological explanation for the observed lower levels of periostin in sputum. It has been shown that periostin is strongly expressed at the RNA level in epithelial cells but protein expression could not be detected in these cells [6, 7]. However, periostin is immunolocalized to the basement membrane immediately below the epithelial cells as well as mesenchymal cells [7]. This discrepancy between RNA and protein expression has led to the postulation that periostin protein is rapidly secreted by airway epithelial cells into the subepithelial layer. In vitro tissue culture experiments using an air/liquid interface, representing the airway lumen and bronchial tissue respectively, support this hypothesis, as periostin was abundantly present in the basal medium, but could not be detected in the apical washes [7]. It is therefore feasible that periostin may not be present in high concentrations in the sputum supernatant collected from the airway lumen. Alternately, the low sputum periostin levels may represent plasma leakage or the presence of periostin in the sputum supernatant may indicate a sub-group of patients who have a specific alteration in the epithelial barrier in some way or suggest a different cellular source of periostin in the sputum samples.

The utility of identifying eosinophilic asthma is well established with improved management and reduced exacerbations as key outcomes [1, 15]. However, sputum induction is not widely available and is unlikely to be adopted into routine clinical practice. As such, there is an unmet need for surrogate biomarkers to assist clinical
decision making in asthma. Despite a statistically significant correlation between both serum and sputum periostin and the sputum eosinophil proportions, the strength of the association was relatively modest such that neither sputum nor serum periostin levels could sufficiently predict the presence of an eosinophilic inflammatory subtype with AUC in the poor to fair range [16]. We then compared blood eosinophils and serum periostin levels as surrogates to identify patients with eosinophilic asthma as identified by sputum eosinophils ≥3%. In agreement with Wagener et al. [17], we found blood eosinophils were an accurate predictor of patients with eosinophilic asthma (AUC 0.829) and serum periostin did not adequately distinguish eosinophilic from non-eosinophilic asthma in adults. Sputum periostin similarly lacked the rigor to be an adequate biomarker to detect eosinophilic asthma in adults with poorly-controlled asthma being neither sensitive nor specific and has the added disadvantage of not being easily accessible in clinical practice. In the BOBCAT study, serum periostin measured using the ELISA platform was found to be a sensitive but not specific marker of airway eosinophilia and performed better than blood eosinophils at predicting the presence of airway eosinophilia as defined by eosinophils in both sputum and tissue [4]. Of course, all studies so far including the current study reported here may be limited by the numbers of participants included with varying patient characteristics, levels of treatment and severity of asthma, and larger studies may provide more insight into the ability of serum periostin to predict the presence of eosinophilic asthma.

There are limited studies supporting the utility of periostin in the management of asthma. There is evidence that periostin levels can indicate better treatment outcomes in studies involving the IL-13 monoclonal antibody lebrikizumab or anti-IgE antibody omalizumab [8, 13, 18]. In these studies blood eosinophils and fractional exhaled nitric oxide (FeNO) were also able to identify people with greater benefit and future clinical studies need to determine how each of these biomarkers will be used in clinical practice. While periostin levels may not be suitable as surrogate markers for detecting the presence of eosinophilic asthma, its biomarker utility may lay in its ability to predict treatment response to anti-IL-13 therapy [13, 19], although this has yet to be tested in prospective studies.

**Conclusions**

In poorly-controlled asthma treated with inhaled corticosteroids, periostin levels are low in airway secretions, but can be detected. Although sputum and serum periostin levels are significantly related to sputum eosinophil proportions, their ability to predict eosinophilic asthma in poorly-controlled asthma appears relatively modest.

**Consent for publication**

Informed consent was obtained from the participants at the time of recruitment for publication of patient data where their identity was remained confidential.

**Availability of data and materials**

The detailed method describing validation of periostin assay has been included in Additional file 2.

The dataset(s) supporting the conclusions of this article are shown as individual data points in Figs. 1, 2 and 3. An additional file with supplementary table has been provided that includes de-identified individual periostin and inflammatory phenotype data.

**Additional files**

Additional file 1: Table S1. Inflammatory phenotype (sputum), serum and sputum periostin levels of individual patients included in the study. (DOCX 18 kb)

Additional file 2: Periostin assay validation. (DOCX 13 kb)

**Abbreviation**

ACQ6: Asthma Control Questionnaire 6; AUC: area under curve; BAL: bronchoalveolar lavage; BMI: body mass index; DTT: dithiothreitol; FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroids; IQR: interquartile range; ppm: parts per million; Th2: T-helper 2 cells.

**Competing interests**

CH and JJ declare that they are employees of Genentech. Authors’ demonstrate that the data presented for the publication does not compromise anonymity or confidentiality or breach local data protection laws. The authors declare that they have no competing interests and that all the parts presented in this manuscript have not been duplicated elsewhere.

**Authors’ contributions**

JLS conceived the study, participated in the design and coordination, performed the statistical analysis and prepared the manuscript. IAY participated in participant recruitment and assessment and sample collection. JAY participated in participant recruitment and assessment and sample collection. PNR participated in participant recruitment and assessment and sample collection. JWU participated in participant recruitment and assessment and sample collection. CJ participated in participant recruitment and assessment and sample collection. ALJ participated in participant recruitment and assessment and sample collection. CH and JJ declare that they are employees of Genentech. The authors would like to acknowledge the The Asthma and Macrolides: Azithromycin Efficacy and Safety (AMAZES) study who collected and processed the sputum samples from the patients who participated in this study.

**Funding**

The study was supported by our NHMRC project grant. The funding body was not involved in the study design, collection, analysis, data interpretation and manuscript writing.
Author details

1Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Level 2, West Wing, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia. 2Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, NSW, Australia.

2School of Medicine, The University of Queensland, Brisbane, QLD, Australia. 3Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia. 4Department of Thoracic Medicine, The University of Queensland, Brisbane, QLD, Australia. 5Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia. 6Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia. 7Lung Research Laboratory, Hanson Institute, Adelaide, SA, Australia. 8Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. 9School of Medicine and Pharmacology, The University of Western Australia, Crawley, WA, Australia. 10Respiratory Trials, The George Institute for Global Health, Sydney, NSW, Australia. 11Australian School of Advanced Medicine, Macquarie University, Sydney, NSW, Australia. 12Department of Thoracic Medicine, Concord General Hospital, Concord, NSW, Australia. 13Genentech Inc, South San Francisco, CA, USA. 14Woolcock Institute of Medical Research, Glebe, NSW, Australia.

Received: 29 December 2015 Accepted: 21 April 2016
Published online: 30 April 2016

References

1. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9329):1715–21.

2. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483–94.

3. Zhang XY, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014;44(9):1137–45.

4. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647–54. e10.

5. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–95.

6. Woodruff PG, Bousshey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104(40):15858–63.

7. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010;107(32):14170–5.

8. Scheeren H, Aron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;44(1):38–46.

9. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Bousshey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99.

10. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henny RL, Cripps AR, et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998;158:36-41.

11. Simpson JL, Phipps S, Baines KL, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43(3):1067–76.

12. Sherman J, Howleg C, Kincaid H, Sidobre S, Ma L, Rigl T, et al. The eucys per estin assay as a companion diagnostic for the novel asthma drug lebrikizumab. Clin Chem. 2014;60(10 suppl):S25–6.

13. Corren J, Lemaske RF, Hanania NA, Korenblat PE, Parsey MV, Aron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–98.

14. Kim MA, Buhara K, Ohta S, Ono J, Yoon MK, Ban GY, et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2014;113(3):314–20.

15. Jayaram L, Pizzichini MM, Cook RJ. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbation. Eur Respir J. 2006;27:483–94.

16. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics: Official Journal of the Metabolic Society. 2013;9(2):280–99.

17. Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, et al. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–20.

18. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–11.

19. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–56.